Kestra Advisory Services LLC Purchases 17,511 Shares of Novo Nordisk A/S $NVO

Kestra Advisory Services LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 11.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 164,361 shares of the company’s stock after buying an additional 17,511 shares during the period. Kestra Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $6,040,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in NVO. Money Concepts Capital Corp grew its position in shares of Novo Nordisk A/S by 7.2% in the 1st quarter. Money Concepts Capital Corp now owns 123,261 shares of the company’s stock valued at $4,530,000 after acquiring an additional 8,260 shares during the period. Azzad Asset Management Inc. ADV raised its holdings in shares of Novo Nordisk A/S by 49.7% in the 1st quarter. Azzad Asset Management Inc. ADV now owns 98,290 shares of the company’s stock valued at $3,612,000 after purchasing an additional 32,644 shares during the period. Demars Financial Group LLC lifted its stake in Novo Nordisk A/S by 19.9% in the 1st quarter. Demars Financial Group LLC now owns 23,099 shares of the company’s stock valued at $849,000 after purchasing an additional 3,830 shares during the last quarter. Capstone Capital Management Ltd bought a new position in Novo Nordisk A/S during the first quarter worth about $935,000. Finally, Greenwood Capital Associates LLC bought a new position in Novo Nordisk A/S during the first quarter worth about $531,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NVO. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Wolfe Research started coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $65.56.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk won EU approval for its once-daily Wegovy pill, making it the first oral GLP-1 weight-loss treatment cleared across the European Union and expanding its obesity market reach. Novo Nordisk wins EU approval for Wegovy weight-loss pill
• Positive Sentiment: Novo Nordisk updated investors on a large Phase 3 heart failure-obesity study, suggesting continued pipeline progress in cardiometabolic disease, a major long-term growth area. Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial
• Positive Sentiment: Fresh hemophilia trial results for Mim8/concizumab showed sustained efficacy and safety, expanding evidence for Novo’s rare blood disorder portfolio. Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children
• Positive Sentiment: Novo Nordisk said most patients are choosing its obesity pill over Eli Lilly’s newer entrant, reinforcing confidence in its competitive position in the weight-loss drug market. It’s been three months since Lilly launched its obesity pill. Most people are taking Novo’s pill instead.
• Neutral Sentiment: Novo Nordisk also signed an agreement to evaluate a semaglutide implant, an early-stage move that adds optionality but is too preliminary to affect near-term results. Novo Nordisk signs pact to assess semaglutide implant
• Negative Sentiment: Sun Pharma won South Africa approval to launch a generic version of semaglutide, highlighting rising competitive pressure on Novo’s diabetes and obesity blockbusters. India’s Sun Pharma wins South Africa approval to launch generic Ozempic
• Negative Sentiment: Zacks Research downgraded Novo Nordisk to “strong sell,” which could weigh on sentiment despite the company’s positive operating news. Novo Nordisk A/S was downgraded by Zacks Research from “hold” to “strong sell”

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $50.56 on Thursday. The stock has a 50 day simple moving average of $45.89 and a 200 day simple moving average of $45.80. The stock has a market cap of $225.77 billion, a P/E ratio of 11.87, a PEG ratio of 4.48 and a beta of 0.77. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $71.79. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Research analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.